242 related articles for article (PubMed ID: 17147833)
1. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis.
Cleary SM; McIntyre D; Boulle AM
Cost Eff Resour Alloc; 2006 Dec; 4():20. PubMed ID: 17147833
[TBL] [Abstract][Full Text] [Related]
2. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
3. Assessing efficiency and costs of scaling up HIV treatment.
Cleary SM; McIntyre D; Boulle AM
AIDS; 2008 Jul; 22 Suppl 1():S35-42. PubMed ID: 18664951
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study.
Estill J; Egger M; Blaser N; Vizcaya LS; Garone D; Wood R; Campbell J; Hallett TB; Keiser O;
AIDS; 2013 Jun; 27(9):1483-92. PubMed ID: 23462219
[TBL] [Abstract][Full Text] [Related]
5. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
6. Does directly administered antiretroviral therapy represent good value for money in sub-Saharan Africa? A cost-utility and value of information analysis.
Uthman RT; Sutton AJ; Jackson LJ; Uthman OA
PLoS One; 2018; 13(1):e0191465. PubMed ID: 29360841
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
[TBL] [Abstract][Full Text] [Related]
8. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.
Meyer-Rath G; Pienaar J; Brink B; van Zyl A; Muirhead D; Grant A; Churchyard G; Watts C; Vickerman P
PLoS Med; 2015 Sep; 12(9):e1001869. PubMed ID: 26327271
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda.
Babigumira JB; Sethi AK; Smyth KA; Singer ME
Pharmacoeconomics; 2009; 27(11):963-73. PubMed ID: 19888795
[TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
[TBL] [Abstract][Full Text] [Related]
13. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of nurse-led versus doctor-led antiretroviral treatment in South Africa: pragmatic cluster randomised trial.
Barton GR; Fairall L; Bachmann MO; Uebel K; Timmerman V; Lombard C; Zwarenstein M
Trop Med Int Health; 2013 Jun; 18(6):769-77. PubMed ID: 23480523
[TBL] [Abstract][Full Text] [Related]
16. One world, one hope: the cost of providing antiretroviral therapy to all nations.
Hogg RS; Weber AE; Craib KJ; Anis AH; O'Shaughnessy MV; Schechter MT; Montaner JS
AIDS; 1998 Nov; 12(16):2203-9. PubMed ID: 9833862
[TBL] [Abstract][Full Text] [Related]
17. Corneal Collagen Cross-Linking in the Management of Keratoconus in Canada: A Cost-Effectiveness Analysis.
Leung VC; Pechlivanoglou P; Chew HF; Hatch W
Ophthalmology; 2017 Aug; 124(8):1108-1119. PubMed ID: 28457614
[TBL] [Abstract][Full Text] [Related]
18. Cost and cost-effectiveness of transitioning to universal initiation of lifelong antiretroviral therapy for all HIV-positive pregnant and breastfeeding women in Swaziland.
Cunnama L; Abrams EJ; Myer L; Gachuhi A; Dlamini N; Hlophe T; Kikuvi J; Langwenya N; Mthethwa S; Mudonhi D; Nhlabatsi B; Nuwagaba-Biribonwoha H; Okello V; Sahabo R; Zerbe A; Sinanovic E
Trop Med Int Health; 2018 Sep; 23(9):950-959. PubMed ID: 29956426
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
